{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:05:02Z","timestamp":1762027502986,"version":"build-2065373602"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Science and Technology of the People's Republic of China","award":["2015ZX10003001002"],"award-info":[{"award-number":["2015ZX10003001002"]}]},{"name":"the Ministry of Science and Technology of the People's Republic of China","award":["2017ZX09304009"],"award-info":[{"award-number":["2017ZX09304009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>We aimed to investigate the effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti- tuberculosis (TB) drugs in Chinese population. Newly diagnosed TB patients administered the anti-TB drugs under fasting conditions orally, and then had prepared breakfast at 30\u200aminutes and 120\u200amin after dosing, respectively. Blood sampling was also performed 120\u200a minutes after dosing for the detection of <jats:italic toggle=\"yes\">C<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub> purpose. Overall, twenty-five participants were included in our analysis. The <jats:italic toggle=\"yes\">C<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub>s of 30\u200a minutes interval and 120\u200a minutes interval were 21.8\u200a\u00b1\u200a2.0 and 19.2\u200a\u00b1\u200a2.0\u200a\u03bcg\/mL for rifampin, 1.6\u200a\u00b1\u200a0.2 and 2.1\u200a\u00b1\u200a0.2\u200a\u03bcg\/mL for isoniazid (INH), 1.5\u200a\u00b1\u200a0.1and 1.5\u200a\u00b1\u200a0.2\u200a\u03bcg\/mL for ethambutol (EMB), and 49.2\u200a\u00b1\u200a3.7 and 41.5\u200a\u00b1\u200a3.9\u200a\u03bcg\/mL for pyrazinamide, respectively. Statistical analysis revealed that there was no statistical difference between 2 groups. Additionally, 88.0% and 72.0% of the 25 participants at 2-hour interval group had peak concentrations less than the lower limit of the reference range for INH and EMB, respectively. The <jats:italic toggle=\"yes\">C<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub>s of INH were 0.9\u200a\u00b1\u200a0.4\u200a\u03bcg\/ml for rapid acetylator, which was significantly lower than those of intermediate (1.4\u200a\u00b1\u200a1.0\u200a\u03bcg\/mL), and slow acetylator (2.5\u200a\u00b1\u200a1.0\u200a\u03bcg\/mL), respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01). In conclusion, our data demonstrate that early food intake at 30\u200aminutes after drug administration had no significant influence on the plasma concentrations. In addition, a high proportion of patients receiving first-line anti-TB regimen fail to achieve the expected plasma drug ranges of INH and EMB (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022258","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T19:02:58Z","timestamp":1603911778000},"page":"e22258","source":"Crossref","is-referenced-by-count":5,"title":["Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population"],"prefix":"10.1097","volume":"99","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Du","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Guo","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiqin","family":"Han","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[{"name":"Tuberculosis Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-2600(15)00063-6","article-title":"Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies","volume":"3","author":"Zumla","year":"2015","journal-title":"Lancet Respir Med"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkv394","article-title":"Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial","volume":"71","author":"Saktiawati","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"R6-20230916","first-page":"218","article-title":"Tuberculosis treatment delivery in Bali: a qualitative study of clinic staff perceptions","volume":"8","author":"Watkins","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R7-20230916","first-page":"806","article-title":"Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis","volume":"14","author":"Lin","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.2042-7158.2011.01406.x","article-title":"NSAIDs: take with food or after fasting?","volume":"64:","author":"Rainsford","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/pgs-2016-0026","article-title":"Rapid identification of the NAT2 genotype in tuberculosis patients by multicolor melting curve analysis Pharmacogenomics","volume":"17","author":"Hu","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R11-20230916","first-page":"62","article-title":"Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in ghanaian children with tuberculosis","author":"Dompreh","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1086\/431984","article-title":"Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana","volume":"41","author":"Tappero","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/514513","article-title":"Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis","volume":"25","author":"Choudhri","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"50","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1984.tb02377.x","article-title":"Rifampicin kinetics in undernutrition","volume":"17","author":"Polasa","year":"1984","journal-title":"Br J Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:57:01Z","timestamp":1694829421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":16,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022258","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}